Hematology

Kerry Rogers, MD, breaks down the clinical and lifestyle factors that drive frontline treatment selection between BTK inhibitors and venetoclax regimens.

Discussions highlighted implementing innovative treatments and ensuring patients treated in the community setting have equitable access to advanced therapeutics.

This new analysis highlights zanubrutinib’s survival benefits and lower cardiac toxicity in chronic lymphocytic leukemia.

New review details biologic, psychosocial, and treatment barriers shaping outcomes in AYA acute lymphoblastic leukemia (ALL).

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know about managing infections and CRS.

Adam Kittai, MD, weighs the favorable safety profile of acalabrutinib plus venetoclax against lingering unknowns on long-term efficacy and high-risk patients.

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”

Efficacy and safety top the list for patients and physicians making R/R CLL treatment decisions, yet fewer than 1 in 3 patients felt their doctor fully answered their questions.

Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.

Bidirectional endoscopy (upper endoscopy and colonoscopy) was underutilized in the evaluation of new-onset iron deficiency anemia in younger veterans from 2005 to 2019.

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.

Taiho submitted the supplemental new drug application in April 2025 for decitabine/cedazuridine and venetoclax, and the FDA accepted it for review in July 2025.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

Community pharmacists must build scalable workflows as bispecific antibodies move into earlier lines and outpatient settings, notes Brooke Peters, PharmD, BCOP, of AON.

Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.

For BTK inhibitor selection in frontline CLL treatment, age, risk profile, and long-term sequencing strategy influence treatment decisions, says Kerry Rogers, MD.

Philadelphia oncology leaders tackle gaps in biomarker testing, breast cancer advances, myeloma innovation, and clinical trial equity.

Experts discussed value-based oncology care, CAR T-cell therapy access gaps, myeloma advances, and bispecific therapy challenges.

Karen Fancher, PharmD, BCOP, emphasizes a pharmacist’s pivotal role in CLL care through communication, adherence strategies, and bridging patients with medical teams.

A consensus definition of high genomic complexity in chronic lymphocytic leukemia may be less important than analyzing the contributions of individual biomarkers.

A case study shows positive outcomes following allogeneic stem cell transplantation in a patient with highly refractory MM and therapy-related MDS/AML.

A French real-world study of 282 patients with CLL identified 2 distinct treatment profiles shaped by age, genetics, and logistics—not trial data alone.

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.